胃肠道癌症的免疫疗法
Immunotherapy in gastrointestinal cancers.
作者信息
Grierson Patrick, Lim Kian-Huat, Amin Manik
机构信息
Division of Oncology, Department of Internal Medicine, Washington University School of Medicine, Saint Louis, MO, USA.
出版信息
J Gastrointest Oncol. 2017 Jun;8(3):474-484. doi: 10.21037/jgo.2017.05.01.
Abstract
Gastrointestinal (GI) cancers such as gastric, esophageal, pancreas, hepatobiliary, colorectal and anal cancers are a major cause of cancer related mortality worldwide. Traditional treatment options such as chemotherapy, surgery, radiation therapy, monoclonal antibodies and anti-angiogenic agents have been the backbone of treatment of GI cancers in various stages. Current cancer research is moving forward to incorporate immunotherapies in the treatment of GI cancers either as single agent or in combination with current available treatment modalities. This review summarizes the existing and ongoing immunotherapies in the treatment of GI cancers.
摘要
胃肠道（GI）癌症，如胃癌、食管癌、胰腺癌、肝胆癌、结直肠癌和肛管癌，是全球癌症相关死亡的主要原因。传统的治疗选择，如化疗、手术、放疗、单克隆抗体和抗血管生成药物，一直是各阶段胃肠道癌症治疗的支柱。目前的癌症研究正在向前发展，将免疫疗法纳入胃肠道癌症的治疗中，无论是作为单一药物还是与现有的治疗方式联合使用。这篇综述总结了目前和正在进行的用于治疗胃肠道癌症的免疫疗法。
相似文献
1
Immunotherapy in gastrointestinal cancers.
J Gastrointest Oncol. 2017 Jun;8(3):474-484. doi: 10.21037/jgo.2017.05.01.
2
The potential role of immunotherapy to treat colorectal cancer.
Expert Opin Investig Drugs. 2015 Mar;24(3):329-44. doi: 10.1517/13543784.2015.985376. Epub 2014 Dec 17.
3
Current approaches to immunotherapy in noncolorectal gastrointestinal malignancies.
Clinics (Sao Paulo). 2018 Oct 18;73(suppl 1):e510s. doi: 10.6061/clinics/2018/e510s.
4
Targeting the PD-1 pathway: a new hope for gastrointestinal cancers.
Curr Med Res Opin. 2017 Apr;33(4):749-759. doi: 10.1080/03007995.2017.1279132. Epub 2017 Jan 31.
5
Checkpoint inhibitors in gastrointestinal cancers: Expectations and reality.
World J Gastroenterol. 2017 May 7;23(17):3017-3021. doi: 10.3748/wjg.v23.i17.3017.
6
Developments in immunotherapy for gastrointestinal cancer.
Minerva Chir. 2015 Aug;70(4):217-30. Epub 2015 Apr 28.
7
Immunotherapy for GI Malignancies, Ready for Prime Time?
Ann Surg Oncol. 2023 Mar;30(3):1787-1793. doi: 10.1245/s10434-022-12668-w. Epub 2022 Oct 22.
8
Current and emerging anti-angiogenic therapies in gastrointestinal and hepatobiliary cancers.
Front Oncol. 2022 Oct 10;12:1021772. doi: 10.3389/fonc.2022.1021772. eCollection 2022.
9
Harnessing the abscopal effect for gastrointestinal malignancies in the era of immunotherapy.
J Gastrointest Oncol. 2023 Jun 30;14(3):1613-1625. doi: 10.21037/jgo-23-105. Epub 2023 Jun 2.
10
Identification of genomic features associated with immunotherapy response in gastrointestinal cancers.
World J Gastrointest Oncol. 2019 Apr 15;11(4):270-280. doi: 10.4251/wjgo.v11.i4.270.
引用本文的文献
1
Challenges and Opportunities for Precision Surgery for Colorectal Liver Metastases.
Cancers (Basel). 2024 Jun 28;16(13):2379. doi: 10.3390/cancers16132379.
2
Visualization analysis of research hotspots and trends on gastrointestinal tumor organoids.
World J Gastrointest Oncol. 2024 Jun 15;16(6):2826-2841. doi: 10.4251/wjgo.v16.i6.2826.
3
Redefining the battle against colorectal cancer: a comprehensive review of emerging immunotherapies and their clinical efficacy.
Front Immunol. 2024 Mar 12;15:1350208. doi: 10.3389/fimmu.2024.1350208. eCollection 2024.
4
Body Composition and Clinical Outcomes in Esophageal Cancer Patients Treated with Immune Checkpoint Inhibitors.
Ann Surg Oncol. 2024 Jun;31(6):3839-3849. doi: 10.1245/s10434-024-15093-3. Epub 2024 Feb 29.
5
LncRNA-MUF: A Novel Oncogenic Star with Potential as a Biological Marker and Therapeutic Target for Gastrointestinal Malignancies.
J Cancer. 2024 Jan 21;15(6):1498-1510. doi: 10.7150/jca.91984. eCollection 2024.
6
C-type lectin receptor Dectin-1 blockade on tumour-associated macrophages improves anti-PD-1 efficacy in gastric cancer.
Br J Cancer. 2023 Sep;129(4):721-732. doi: 10.1038/s41416-023-02336-5. Epub 2023 Jul 8.
7
Vista of the Future: Novel Immunotherapy Based on the Human V-Set Immunoregulatory Receptor for Digestive System Tumors.
Int J Mol Sci. 2023 Jun 9;24(12):9945. doi: 10.3390/ijms24129945.
8
Intratumour Fusobacterium nucleatum and immune response to oesophageal cancer.
Br J Cancer. 2023 Apr;128(6):1155-1165. doi: 10.1038/s41416-022-02112-x. Epub 2023 Jan 4.
9
Tumor buster - where will the CAR-T cell therapy 'missile' go?
Mol Cancer. 2022 Oct 19;21(1):201. doi: 10.1186/s12943-022-01669-8.
10
Coating bacteria for anti-tumor therapy.
Front Bioeng Biotechnol. 2022 Sep 15;10:1020020. doi: 10.3389/fbioe.2022.1020020. eCollection 2022.
本文引用的文献
1
T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer.
N Engl J Med. 2016 Dec 8;375(23):2255-2262. doi: 10.1056/NEJMoa1609279.
2
Mismatch Repair Deficiency and Response to Immune Checkpoint Blockade.
Oncologist. 2016 Oct;21(10):1200-1211. doi: 10.1634/theoncologist.2016-0046. Epub 2016 Jul 13.
3
Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy.
Nat Med. 2016 Aug;22(8):851-60. doi: 10.1038/nm.4123. Epub 2016 Jul 4.
4
Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial.
Lancet Oncol. 2016 Jun;17(6):717-726. doi: 10.1016/S1470-2045(16)00175-3. Epub 2016 May 3.
5
Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial.
Lancet Oncol. 2016 May;17(5):651-62. doi: 10.1016/S1470-2045(16)00078-4. Epub 2016 Apr 4.
6
Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability.
Immunity. 2016 Mar 15;44(3):698-711. doi: 10.1016/j.immuni.2016.02.025.
7
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota.
Science. 2015 Nov 27;350(6264):1079-84. doi: 10.1126/science.aad1329. Epub 2015 Nov 5.
8
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy.
Science. 2015 Nov 27;350(6264):1084-9. doi: 10.1126/science.aac4255. Epub 2015 Nov 5.
9
Molecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer Immunotherapy.
Clin Cancer Res. 2015 Dec 15;21(24):5427-33. doi: 10.1158/1078-0432.CCR-15-0420. Epub 2015 Oct 30.
10
Developments in cancer vaccines for hepatocellular carcinoma.
Cancer Immunol Immunother. 2016 Jan;65(1):93-9. doi: 10.1007/s00262-015-1728-y. Epub 2015 Jun 21.
Zotero 插件